Berlex Yaz gains acne claim
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Berlex's oral contraceptive Yaz (drospirenone/ethinyl estradiol) clears FDA Jan. 26 for the treatment of moderate acne vulgaris in women who desire an oral contraceptive for birth control. Based on two six-month trials in more than 1,000 patients, the oral contraceptive showed significant reduction in inflammatory and noninflammatory lesion counts. The approval marks the third indication for Yaz, which is also indicated for treatment of emotional and physical symptoms of premenstrual dysphoric disorder (1Pharmaceutical Approvals Monthly October 2006, p. 5)...
You may also be interested in...
Approvals In Brief
Genentech Avastin lung cancer claim clears FDA, while Merck’s new molecular entity Zolinza (vorinostat) is approved for cutaneous T-cell lymphoma. Schering-Plough’s novel antifungal Noxafil (posaconazole) is the first treatment cleared for prevention of invasive Aspergillus infection. Genentech/Biogen Idec’s Rituxan (rituximab) gains a third NHL-related claim with approval of two new indications; Johnson & Johnson’s established anti-TNF agent Remicade (infliximab) expands into the dermatology segment with approval for psoriasis. More approvals in brief
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.